Skip to main content
Clinical trial efficacy data
Navbar Image
Clinical trial efficacy data
This site is intended only for US healthcare professionals.

Clinical trial efficacy data

Lower incidence of chemotherapy dose reductions and delays in clinical trials1-4

  • Fewer dose reductions or delays occurred in patients receiving COSELA in clinical trials across several chemotherapy regimens, including1-4:
    • Etoposide/carboplatin/atezolizumab (secondary endpoint)
    • Etoposide/carboplatin (exploratory endpoint)
    • Topotecan (secondary endpoint)
  • In treatment groups receiving COSELA, infusion interruptions due to an adverse reaction occurred in 4.1% of patients
1L=first-line; 2L=second-line; 3L=third-line.
a
In the pivotal study, no dosage adjustments of atezolizumab were allowed.4
b
Dose reductions were secondary endpoints for pivotal study and study 3.1,3
c
Study 2 was a proof-of-concept study with the primary objectives of assessing safety and tolerability; efficacy objectives were secondary or exploratory.2
d
Dose delays may occur for hematologic toxicity or other factors.1